Clinical trial
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT01401959
Study timeline
Study start (actual)2011-09-23Date precision: day
Registry last updated2018-06-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Breast Cancerunresolved
Interventions
EribulinDRUG · verified · RxNorm: eribulin
TrastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
SCRI Development Innovations, LLClead sponsor
Eisai Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01401959 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.